WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced the immediate appointment of Ashley Kline as Chief Commercial Officer. With a proven history of launching therapies for rare diseases, Ms. Kline is expected to play a pivotal role in advancing Palvella’s commercial operations and strategic objectives.
Ms. Kline previously served as Global Biotech Head and U.S. General Manager at Dompé Pharmaceuticals, where she spearheaded the successful launch of Oxervate®, a groundbreaking topical therapy for neurotrophic keratitis (NK). Under her leadership, Oxervate surpassed $500 million in annual U.S. sales within five years of its FDA approval in 2018. Her innovative launch strategy, marked by high-impact physician outreach and education, established Oxervate as one of the top-performing non-oncology orphan drugs in recent years.
“Ashley is a proven commercial executive in rare diseases and we are thrilled to welcome her to the Palvella team,” said Wes Kaupinen, Founder and Chief Executive Officer. “Ashley brings a dynamic, results-driven approach and deep knowledge of the key factors for achieving success in launching the first FDA-approved therapy for a serious, rare disease. Her leadership was instrumental to Oxervate’s success which is widely regarded as one of the top rare disease launches over the last decade. Ashley’s strong patient-orientation, her ability to build and lead high performing teams, and her analytically driven approach will contribute to Palvella achieving our vision of building the leading rare disease biopharmaceutical company focused on serious, rare genetic skin diseases.”
Ms. Kline’s background also includes roles at Genentech, Santen Pharmaceuticals, and Adverum Biotech. Additionally, she worked as a consultant for Bain and Company. She holds an M.B.A. from Northwestern University’s Kellogg School of Management and a B.A. with distinction from the University of North Carolina at Chapel Hill.
Expressing her enthusiasm for her new role, Ms. Kline stated, “This is an exciting time to join Palvella as the Company has the potential to market the first and only therapeutic option for patients suffering from microcystic lymphatic malformations and cutaneous venous malformations, both rare and debilitating genetic diseases that significantly impact quality of life. I look forward to building out Palvella’s commercial organization and working alongside a team that shares my passion and sense of responsibility to reduce the burden of illness, especially in areas of high unmet medical need.”
With this appointment, Palvella Therapeutics continues its focused efforts on addressing rare genetic skin diseases, an area with considerable unmet medical needs and significant opportunities for innovation.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.